Understanding ABECMA® (idecabtagene vicleucel)

Understanding ABECMA® (idecabtagene vicleucel) focuses on the first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy approved by the U.S. Food and Drug Administration (FDA) for use in myeloma. Abecma (also known as "ide-cel") is the first CAR T-cell therapy to be approved by the FDA for patients with myeloma, and it is the first CAR T-cell therapy approved by the FDA that targets BCMA.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.